Adient (ADNT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
21 Jan, 2026Executive summary
The 2026 Annual General Meeting will be held on March 10, 2026, in Dublin, Ireland, with shareholders voting on director elections, auditor ratification, executive compensation, and share issuance authorities.
Shareholders of record as of January 14, 2026, are eligible to vote, with multiple voting methods available, including online, phone, mail, or in person.
Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact, with paper copies available upon request.
Voting matters and shareholder proposals
Eight directors are nominated for one-year terms; all are current directors, with 50% gender or racially/ethnically diverse.
Proposals include ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of executive compensation, renewal of Board authority to issue shares, and opt-out of statutory preemption rights.
Shareholder proposals for the 2027 meeting must be submitted between September 23 and December 10, 2026, following SEC and company guidelines.
Board of directors and corporate governance
The Board consists of eight members, 87.5% independent, with separated Chair and CEO roles and an independent Chair.
Committees (Audit, Human Capital and Compensation, Corporate Governance) are fully independent; regular executive sessions are held.
Board succession, diversity, and annual evaluations are emphasized; proxy access rights are granted to shareholders.
Latest events from Adient
- Q1 FY26 saw 4% revenue growth and raised guidance, driven by China, innovation, and new wins.ADNT
Q1 20264 Feb 2026 - Disciplined capital allocation, innovation, and regional growth drive margin expansion and value.ADNT
Deutsche Bank Global Auto Industry Conference 20253 Feb 2026 - Margin expansion and innovation drive growth, with China focus and restructuring prioritized.ADNT
J.P. Morgan Auto Conference 20242 Feb 2026 - Q3 sales dropped 8% and net loss hit $11M, but cash flow and buybacks stayed strong.ADNT
Q3 20242 Feb 2026 - Director elections, auditor ratification, and Board authority renewals up for shareholder vote.ADNT
Proxy Filing21 Jan 2026 - Margin expansion and strong cash flow in FY24, with China and EMEA as key focus areas.ADNT
Q4 202415 Jan 2026 - Q1 FY2025: $196M EBITDA, $45M cash flow, EMEA weak, guidance trimmed, liquidity strong.ADNT
Q1 20259 Jan 2026 - Director elections, auditor ratification, and executive pay alignment headline the 2025 agenda.ADNT
Proxy Filing1 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and key governance proposals.ADNT
Proxy Filing1 Dec 2025